Ribotoxic Stress through p38 Mitogen-activated Protein Kinase Activates in Vitro the Human Pyrin Inflammasome by �쑀�젣�슧
Alnemri
Teresa Fernandes-Alnemri and Emad S. 
Je-Wook Yu, Andrew Farias, Inhwa Hwang,
  
 the Human Pyrin Inflammasomein Vitro
ActivatesMitogen-activated Protein Kinase 
Ribotoxic Stress through p38
Signal Transduction:
doi: 10.1074/jbc.M112.448795 originally published online March 11, 2013
2013, 288:11378-11383.J. Biol. Chem. 
  
 10.1074/jbc.M112.448795Access the most updated version of this article at doi: 
  
.JBC Affinity SitesFind articles, minireviews, Reflections and Classics on similar topics on the 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/288/16/11378.full.html#ref-list-1
This article cites 31 references, 7 of which can be accessed free at
 at Y
O
N
SEI U
N
IV
ERSITY
 on M
ay 20, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
 at Y
O
N
SEI U
N
IV
ERSITY
 on M
ay 20, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Ribotoxic Stress through p38 Mitogen-activated Protein
Kinase Activates in Vitro the Human Pyrin Inflammasome*
Received for publication,December 24, 2012, and in revised form, March 7, 2013 Published, JBC Papers in Press,March 11, 2013, DOI 10.1074/jbc.M112.448795
Je-Wook Yu‡§1, Andrew Farias‡, Inhwa Hwang§, Teresa Fernandes-Alnemri‡, and Emad S. Alnemri‡2
From the ‡Department of Biochemistry andMolecular Biology and the Kimmel Cancer Center, Thomas Jefferson University,
Philadelphia, Pennsylvania 19107 and the §Department of Microbiology and Immunology, Yonsei University College of Medicine,
Seoul 120-752, Korea
Background: Human pyrin is an important regulator of inflammation and is involved in the pathogenesis of familial
Mediterranean fever (FMF).
Results: Ribotoxic stress activates the human pyrin inflammasome.
Conclusion: p38 MAPK signaling is required for assembly of the human pyrin inflammasome.
Significance: Understanding the mechanism of activation of the pyrin inflammasome is crucial for the development of thera-
peutics to treat FMF.
Human pyrin with gain-of-function mutations in its B30.2/
SPRY domain causes the autoinflammatory disease familial
Mediterranean fever by assembling an ASC-dependent inflam-
masome that activates caspase-1. Wild-type human pyrin can
also form an inflammasome complex with ASC after engage-
ment by autoinflammatory PSTPIP1 mutants. How the pyrin
inflammasome is activated in the absence of disease-associated
mutations is not yet known.We report here that ribotoxic stress
triggers the assembly of the human pyrin inflammasome, lead-
ing to ASC oligomerization and caspase-1 activation in THP-1
macrophages and in a 293T cell line stably reconstituted with
components of the pyrin inflammasome. Knockdown of pyrin
and selective inhibition of p38 MAPK greatly attenuated
caspase-1 activation by ribotoxic stress, whereas expression of
the conditional mutant MEKK3:ER* allowed the activation of
caspase-1 without ribotoxic stress. Disruption of microtubules
by colchicine also inhibited pyrin inflammasome activation by
ribotoxic stress. Together, our results indicate that ribotoxic
stress activates the human pyrin inflammasome through a
mechanism that requires p38MAPK signaling andmicrotubule
stability.
Pathogens andmetabolic danger signals trigger the assembly
of cytoplasmic multiprotein complexes termed inflam-
masomes, which serve as molecular scaffolds for the activation
of caspase-1 in innate immune cells (1, 2). Activated caspase-1
processes inactive pro-IL-1 and pro-IL-18 into the active
cytokines IL-1 and IL-18, respectively. It is also involved in the
unconventional secretion of these cytokines and other proin-
flammatory mediators such as HMGB1 (high-mobility group
box 1) (3). Deregulated inflammasome activity can lead to several
autoinflammatory periodic fever syndromes in humans such as
theMuckle-Wells, familialMediterranean fever (FMF),3 and pyo-
genic arthritis, pyoderma gangrenosum, and acne (PAPA) syn-
dromes (4, 5). This has also been implicated in chronic inflam-
matory and metabolic diseases such as gout, atherosclerosis,
silicosis, and type 2 diabetes (6, 7).
FMF is caused by mutations in the MEFV gene, which
encodes pyrin (8, 9), but the molecular mechanism by which
thesemutations lead to increased production of IL-1 is not yet
clear. Cell-based reconstitution studies in our laboratory dem-
onstrated that human pyrin can form an inflammasome com-
plex with ASC (apoptosis-associated speck-like protein con-
taining a caspase recruitment domain) and procaspase-1,
leading to ASC oligomerization, caspase-1 activation, and pro-
IL-1 processing (10). Furthermore, our studies showed that
binding of autoinflammatory PAPA-associated PSTPIP1
(proline-serine-threonine phosphatase-interacting protein
1) mutants to human pyrin can activate the pyrin inflam-
masome, leading to increased IL-1 production (5). Based on
these studies, it was proposed that wild-type pyrin is a proin-
flammatory mediator capable of activating caspase-1 and that
FMF-associated pyrin mutations may represent gain-of-func-
tion mutations that deregulate pyrin inflammasome activation
(10). In support of this, recent studies in mice have shown that
expression of humanized pyrin proteins carrying FMF-associ-
ated mutations results in exaggerated IL-1 cytokine produc-
tion and severe autoinflammation (11). Despite these recent
developments, the role of pyrin in the activation of caspase-1
remains unclear.
The p38MAPKs play important roles in various intracellular
responses, including proliferation, differentiation, apoptosis,
tumorigenesis, and inflammation (12). Activation of p38
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MAPKs has been shown to increase production of proinflam-
matory cytokines, and their specific inhibition potently blocks
production of these cytokines and reduces chronic inflamma-
tion in inflammatory diseases such as rheumatoid arthritis and
inflammatory bowel diseases (13). The mechanism by which
p38 MAPKs increase production of proinflammatory cyto-
kines, particularly IL-1 and IL-18, is not fully understood. In
this study, we investigated whether p38 MAPKs play a role in
activation of the pyrin inflammasome. We provide evidence
that the activation of p38 MAPK by ribotoxic stress can trigger
formation of a pyrin inflammasome, resulting in the oligomer-
ization of ASC and the subsequent activation of caspase-1.
EXPERIMENTAL PROCEDURES
Antibodies and Reagents—Antibodies against caspase-1,
pyrin, IL-1, and NLRP3 have been described previously (5, 14,
15). Anti-ASC antibody was from Santa Cruz Biotechnology.
Anti-phospho-p38 and anti-p38 antibodies were fromCell Sig-
naling. Anti-JNK antibody was from BD Biosciences. Anti-
FLAG antibody, anisomycin, deoxynivalenol (DON; vomi-
toxin), 4-hydroxytamoxifen (4-HT), colchicine, paclitaxel,
nigericin, LPS, and cycloheximide were from Sigma. SB203580
and SP600125 were from EMD Biosciences. Anti-phospho-
JNK antibody and recombinant human IFNwas from Invitro-
gen. The plasmid encoding MEKK3:ER* was a kind gift from
S. J. Cook.
siRNA Knockdown—Knockdown of pyrin was performed by
transfection of siRNA oligonucleotides targeting human pyrin
(Qiagen). Scrambled siRNA (control) or pyrin-specific siRNA
was transfected into 293T-C1AP or THP-1 cells using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s
protocol.
Cell Treatments and Immunoblot Analysis—293T-C1AP
and 293T-C1AN cells, which stably express N-terminally
FLAG-tagged procaspase-1, ASC, and pyrin or NLRP3, respec-
tively, were generated by stably transfecting 293T-C1A cells
(293T cells expressing procaspase-1 and ASC) with constructs
encoding pyrin or NLRP3 as described previously (5, 14, 16).
Cells were treated with the following drugs as indicated in each
experiment: anisomycin (20M), DON (10M), cycloheximide
(10 g/ml), puromycin (8 g/ml), nigericin (10 M), SB203580
(20 M), SP600125 (20 M), IFN (20 ng/ml), and LPS (500
ng/ml). Cells were lysed in buffer containing 20mMHEPES (pH
7.5), 0.5% Nonidet P-40, 50 mM KCl, 150 mM NaCl, 1.5 mM
MgCl2, 1 mM EGTA, and protease inhibitors. Cell lysates were
fractionated by SDS-PAGE and then transferred to PVDF
membranes (Bio-Rad). In some experiments, cell culture
supernatants were precipitated by methanol/chloroform as
described previously (14) and then immunoblotted with
appropriate antibodies.
Chemical Cross-linking—Chemical cross-linking was per-
formed using disuccinimidyl suberate (DSS; Pierce) as
described previously (5, 17, 18). Briefly, for analysis of pyrin
oligomerization, lysates from IFN-primedTHP-1 cells treated
with orwithout anisomycinwere cross-linkedwithDSS, immu-
noprecipitated with anti-pyrin antibody, and immunoblotted
with anti-pyrin antibody as described (5). For analysis of ASC
oligomerization, THP-1 cells were lysed after stimulation, and
the cell lysates were centrifuged at 6000 rpm for 10 min. The
resulting pellet fractionswere resuspended in PBS, cross-linked
withDSS, and analyzed by immunoblottingwith anti-ASCanti-
body as described previously (17, 18).
RESULTS
Ribotoxic Stress Induces Pyrin-dependent Caspase-1
Activation—Molecular evidence suggests that human pyrin
forms an inflammasome complex with ASC to activate
caspase-1 (5, 10). However, the signaling pathway that engages
and activates the pyrin inflammasome is currently unknown.
Considering that the p38 MAPK stress-signaling pathway is
involved in inflammation and possibly in the activation of
caspase-1 in response to stress (13, 19), we investigated if acti-
vation of the p38 MAPK pathway might activate the pyrin
inflammasome. To this end, we used a 293T cell line stably
reconstituted with the human pyrin inflammasome compo-
nents procaspase-1, ASC, and pyrin (293T-C1AP cells) (5). As a
control, we used a 293T cell line stably reconstituted with the
human NLRP3 inflammasome components procaspase-1,
ASC, and NLRP3, (293T-C1AN cells) (5, 14, 16). The two cell
lines were treated either with anisomycin, a ribosome inhibitor
that potently activates p38 MAPK and JNK by a “ribotoxic
stress response” mechanism (20), or with nigericin, a pore-
forming toxin that activates the NLRP3 inflammasome. As
shown in Fig. 1A, anisomycin treatment induced robust
caspase-1 activation only in the pyrin-expressing 293T-C1AP
cells but not in the NLRP3-expressing 293T-C1AN cells as evi-
denced by the processing of procaspase-1 to the p20 subunit.
Similar results were obtained with the mycotoxin DON (Fig.
1A, third lane), a potent ribosome inhibitor and ribotoxic stress
activator (21). In contrast, the NLRP3 stimulus nigericin was
able to activate caspase-1 only in 293T-C1AN cells, but not in
293T-C1AP cells. Consistent with its well documented effects
(22), anisomycin induced the activation of both p38MAPK and
JNK in 293T-C1AP cells as determined by the phosphorylation
of each kinase (Fig. 1B). These results suggest that ribotoxic
stress can specifically activate the pyrin inflammasome, leading
to robust caspase-1 activation.
FIGURE 1. Specific activation of the pyrin inflammasome by ribotoxic
stress inducers. A, immunoblots of caspase-1, pyrin, NLRP3, and ASC in
lysates of 293T-C1AP or 293T-C1AN cells stimulated with anisomycin (Aniso),
DON, or nigericin (Nig) for 5 h as indicated. Un, untreated. B, immunoblots
of caspase-1, phospho-p38 (P-p38), p38, phospho-JNK (P-JNK), and JNK in
lysates of 293T-C1AP treated with anisomycin for the indicated times.
procasp-1, procaspase-1.
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Ribotoxic Stress-induced Caspase-1 Activation Is Dependent
on p38 MAPK—Because anisomycin induced the activation of
both p38MAPK and JNK in 293T-C1AP cells (Fig. 1B), we next
examined the effect of selective p38 MAPK inhibition on ani-
somycin-induced caspase-1 activation. Pretreatment with
SB203580, which is known to selectively inhibit p38 and p38
MAPKs (13), significantly reduced caspase-1 activation by ani-
somycin in 293T-C1AP cells, whereas the selective JNK inhib-
itor SP600125 showed little effect (Fig. 2, A and B). These
results indicate that p38MAPK activity is required for the acti-
vation of caspase-1 by anisomycin in 293T-C1AP cells. Consis-
tent with these results, ribosome inhibitors that weakly activate
p38 (cycloheximide) or do not activate p38 (puromycin) (23)
induced significantly less or very little caspase-1 activation,
respectively (Fig. 2, C and D).
To provide further evidence that p38 MAPK is involved in
activation of the pyrin inflammasome,we transfected the 293T-
C1AP cells with a construct encoding the conditional protein
kinaseMEKK3:ER (24). TheMEKK3:ER* protein consists of
the kinase domain ofMEKK3 fused in-frame to amodified form
of the hormone-binding domain of the estrogen receptor. The
MEKK3:ER* protein remains inactive until cells are treated
with 4-HT, allowing activation of theMAPK and SAPK kinases
without cellular stress or damage (24). Similar to the anisomy-
cin effect, treatment of the MEKK3:ER*-expressing 293T-
C1AP cells with 4-HT resulted in the activation of caspase-1
(Fig. 2E). Furthermore, selective inhibition of p38 MAPK by
SB203580 reduced MEKK3-mediated caspase-1 activation in
these cells. No caspase-1 activation was observed after 4-HT
stimulation of MEKK3:ER*-expressing 293T-C1A cells (Fig.
2F), which lack pyrin, indicating that pyrin is required for the
activation of caspase-1 in response to activation of the
MEKK3:ER* protein kinase. Taken together, these observa-
tions indicate that p38MAPK is a critical signaling molecule in
the pyrin inflammasome activation pathway.
Knockdown of Pyrin Reduces Caspase-1 Activation by
Anisomycin—To further validate the critical role of pyrin in
caspase-1 activation by activated p38MAPK,we knocked down
pyrin expression in 293T-C1AP cells by siRNA (Fig. 3A, lower
panel). As expected, caspase-1 activation by anisomycin was
notably reduced in cells transfected with pyrin-specific siRNA,
but not in cells transfected with scrambled siRNA (Fig. 3A,
upper panel), indicating that pyrin is indeed required for
caspase-1 activation by anisomycin in these cells.
To provide more evidence supporting the role of pyrin in
caspase-1 activation by activated p38 MAPK, we treated phor-
bol 12-myristate 13-acetate (PMA)-differentiated THP-1 cells
with anisomycin. Unlike 293T-C1AP cells, anisomycin treat-
ment did not trigger caspase-1 activation in PMA-differenti-
ated THP-1 cells (Fig. 3B, second lane). We reasoned that this
unresponsiveness to anisomycin might be due to the low
expression level of pyrin in the PMA-differentiated THP-1 cells
(Fig. 3B, lower panel, first and second lanes). To up-regulate
pyrin expression, we primed THP-1 cells with IFN, which was
shown previously to induce pyrin expression (5). Treatment of
THP-1 cells for 8–24 hwith IFN or LPS induced notable pyrin
up-regulation (Fig. 3C). Stimulation of the IFN-primed
THP-1 cells with anisomycin caused caspase-1 activation as
observed in 293T-C1AP cells (Fig. 3B, fourth lane). Knocking
down pyrin expression by siRNA in the IFN-primed THP-1
cells attenuated caspase-1 activation in response to anisomycin,
but not to nigericin (Fig. 3D). Collectively, these results dem-
onstrate that the pyrin inflammasome is important for the acti-
vation of caspase-1 in response to ribotoxic stress in both the
pyrin inflammasome-reconstituted 293T-C1AP cells and the
human THP-1 macrophage cell line.
Anisomycin Facilitates ASC Oligomerization—To under-
stand how p38 MAPK activation by anisomycin triggers the
pyrin inflammasome assembly, we first determined whether
anisomycin could affect the oligomerization status of pyrin.
Consistent with our previously published results (5), pyrin was
FIGURE 2. p38 MAPK-dependent activation of caspase-1. A and C, immu-
noblots of caspase-1 in lysates of 293T-C1AP cells stimulatedwith anisomycin
(Aniso) for 5 h in the absence (untreated (Un)) or presence of SB203580 (SB) or
SP600125 (SP) (A) or with the indicated drugs for 5 h (C). procasp-1, pro-
caspase-1; Puro, puromycin; CHX, cycloheximide. B and D, quantification
of caspase-1activation inmultiple independentexperimentswith293T-C1AP
cells treated as described for A and C as determined by densitometry of the
caspase-1 p20bandproducedby the different treatments. Percent activation
represents the percentages of the densitometric values of the caspase-1 p20
band produced by the different treatments relative to the densitometric
value of the caspase-1 p20 produced by anisomycin treatment alone (n 3).
*, p 0.001 (Student’s t test). E and F, immunoblots of caspase-1 in lysates of
293T-C1AP (E) or 293T-C1A (F) cells transfected with empty vector (first to
third lanes) or theMEKK3:ER* plasmid (fourth to sixth lanes) for 18 h and then
treated with 4-HT (1 M) for an additional 6 h in the presence or absence of
SB203580 as indicated. The lower panels in A, C, and E show pyrin
immunoblots.
p38MAPK Regulates Activation of the Pyrin Inflammasome
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present as a homotrimer in IFN-primed THP-1 cells (Fig. 4A).
However, anisomycin treatment did not change the oligomeri-
zation status of pyrin, suggesting that anisomycin-induced p38
MAPK signaling acts at the level of ASC recruitment and olig-
omerization (17). Indeed, by using the ASC oligomerization
assay, which measures the amount of oligomeric ASC in the
Nonidet P-40-insoluble low-speed pellets of stimulated cells
(17, 18), we found a high amount of oligomericASC in the pellet
fraction of IFN/anisomycin-treatedTHP-1 cells (Fig. 4B, third
lane), but not in that of untreated or IFN-treated cells (first
and second lanes, respectively). These results suggest that ani-
somycin-induced p38 MAPK signaling promotes the recruit-
ment of ASC to the pyrin homotrimer, which facilitates ASC
oligomerization.
Destabilization ofMicrotubules Inhibits Anisomycin-induced
Caspase-1 Activation—Colchicine, a microtubule-destabiliz-
ing drug, has been clinically used for the treatment of FMF (25).
Although the precise molecular mechanism by which colchi-
cine reduces inflammation in FMF patients remains largely
unknown, we have previously demonstrated that both colchi-
cine and nocodazole blocked pyrin inflammasome-mediated
caspase-1 activation by autoinflammatory PAPA-associated
PSTPIP1mutants (5). To assess the importance of microtubule
polymerization in anisomycin-induced caspase-1 activation,
we stimulated 293T-C1AP cells with anisomycin in the pres-
ence or absence of colchicine. As shown in Fig. 4 (C and D),
colchicine almost completely abrogated anisomycin-induced
caspase-1 activation. In contrast, colchicine treatment signifi-
cantly increased nigericin-induced caspase-1 activation in
293T-C1AN cells (Fig. 4, E and F). These results indicate that
microtubule stability is important for pyrin inflammasome
activation, but not for activation of the NLRP3 inflammasome.
FIGURE 3. Knockdown of pyrin reduces caspase-1 activation in response
to anisomycin.A, immunoblots of caspase-1 andpyrin in cell lysates of 293T-
C1AP cells transfected with non-silencing siRNA (control (Con)) or siRNA spe-
cific to pyrin (Pyr) for 48 h and then treated with anisomycin (Aniso) for 5 h as
indicated. B, immunoblots of caspase-1 in culture supernatants (Sup; upper
panel) or cell lysates (Lys; middle panel) of PMA-differentiated THP-1 cells
treated with () or without () anisomycin (5 h) following priming with or
without IFN for 18 h as indicated. The lower panel shows an immunoblot of
pyrin in the same samples. Theasterisk indicates a nonspecific band.C, immu-
noblots of pyrin, IL-1, and -actin in PMA-differentiated THP-1 cells stimu-
latedwith IFNor LPS for the indicated times.D, immunoblots of caspase-1 in
culture supernatants as determined with anti-caspase-1 p20 antibody (first
panel) or anti-caspase-1 p10 antibody (second panel) of PMA-differentiated
THP-1 cells transfectedwith non-silencingor pyrin-specific siRNA for 48h and
then primed with IFN for an additional 18 h, followed by treatment with
anisomycin or nigericin (Nig) for 5 h as indicated. The third and fourth panels
show immunoblots of procaspase-1 (procasp-1) andpyrin in the lysates of the
same samples. The results are representative of at least three independent
experiments.
FIGURE4.RoleofASCandmicrotubules inanisomycin-inducedcaspase-1
activation. A, PMA-differentiated THP-1 cells were primedwith IFN for 16 h
and then treated with or without anisomycin (Aniso) for 3 h as indicated. Cell
lysates were cross-linked with increasing concentrations of DSS and immu-
noprecipitated with anti-pyrin antibody, followed by immunoblotting with
anti-pyrin antibody.B, immunoblots of oligomeric ASCpyroptosomes inDSS-
cross-linked cell pellets (Pel DSS) of PMA-differentiated THP-1 cells treated
with orwithout anisomycin after IFNpriming as indicated (upper panel). The
middle and lower panels show ASC and pyrin in the cell lysates (Lys) of the
same samples. The asterisk indicates a nonspecific band. C and E, immunob-
lots of caspase-1 in 293T-C1AP cells treatedwith () or without () anisomy-
cin following pretreatment with colchicine (5 M) as indicated (C) or in 293T-
C1AN cells treated with or without nigericin (Nig) following pretreatment
with colchicine (Col; 5 M) as indicated (E). procasp-1, procaspase-1. D and F,
quantification of caspase-1 activation in multiple independent experiments
with 293T-C1AP (D) or 293T-C1AN (F) cells treated as described for C and E as
determined by densitometry of the caspase-1 p20 band produced by the
different treatments. Percent activation represents the percentages of the
densitometric values of the caspase-1 p20 band produced by the different
treatments relative to thedensitometric value of the caspase-1 p20produced
by anisomycin (D) or nigericin (F) treatment alone (n 3). *, p 0.001 (Stu-
dent’s t test). Un, untreated.
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DISCUSSION
FMF is an inherited autoinflammatory disease caused by
missense mutations in human pyrin (8, 9). The exact role of
pyrin in inflammation and the signaling pathway(s) that regu-
late its activity are not fully understood. Earlier studies pro-
posed that pyrin functions as an anti-inflammatorymolecule by
inhibiting the activity or activation of caspase-1 (26). However,
subsequent studies showed that human pyrin can assemble an
inflammasome complex with ASC to activate caspase-1 when
coexpressed in HEK-293T cells or when engaged by PAPA-
associated PSTPIP1 mutants in HEK-293T and human THP-1
macrophages (5, 10). This indicates that pyrin functions as a
mediator rather than as an inhibitor of caspase-1 activation.
This role has been supported by additional studies in macro-
phages (27) and underscored by knock-in studies in mice
expressing humanized pyrin proteins carrying FMF-associated
mutations (11). Using aHEK-293T cell line stably reconstituted
with components of the human pyrin inflammasome and
THP-1 macrophages with pyrin knockdown, our work further
supports the role of pyrin as a mediator of caspase-1 activation
by demonstrating that ribotoxic stress can activate the human
pyrin inflammasome. Several ribosome inhibitors that damage
the 28 S ribosomal RNA and/or interfere with its functioning
can induce a response called the ribotoxic stress response,
which stimulates MAPK signaling (20, 23). Among these, ani-
somycin and the trichothecene mycotoxin DON are two of the
most potent ribotoxic stress inducers and activators of the p38
MAPK pathway (23). Our results demonstrate that these
agents, through their ability to activate p38MAPK, can activate
caspase-1 by a pyrin-dependent mechanism, indicating that
p38 MAPK is a critical mediator of pyrin inflammasome acti-
vation. The key role of p38 in activation of the pyrin inflam-
masome was supported by experiments showing that expres-
sion of the conditional protein kinaseMEKK3:ER* (24), which
allows the activation of p38 MAPK with 4-HT and without
cellular stress or damage, can induce the activation of caspase-1
in 293T-C1AP cells. Furthermore, SB203580, a small molecule
selective inhibitor of p38 MAPK, can effectively suppress
caspase-1 activation by anisomycin and MEKK3:ER*. The
regulation of pyrin activity by p38 MAPK suggests that p38
MAPK inhibitors represent potential therapeutics, alone or in
combination with colchicine, for the treatment of FMF.
The microtubule-disrupting drug colchicine is very effective
in the treatment of FMF, and the colchicine responsiveness is
an important diagnostic tool for FMF (25, 28). Our results sug-
gest that this therapeutic benefit of colchicine is likely due to its
ability to inhibit the activity of the pyrin inflammasome. Treat-
ment of 293T-C1AP cells with colchicine inhibited pyrin-me-
diated caspase-1 activation in response to anisomycin. In
contrast, colchicine treatment had no inhibitory effect on
NLRP3-mediated caspase-1 activation in response to nigericin
in 293T-C1AN cells. These results indicate that the colchicine
responsiveness is highly specific to the pyrin inflammasome
pathway and could explain the therapeutic benefit of colchicine
in the treatment of FMF. It is not yet clear how colchicine can
inhibit the activity of the pyrin inflammasome. However,
because pyrin is associated with microtubules (29), we can
speculate that the disruption of microtubules by colchicine
might lead to dissociation of pyrin from microtubules. This
could prevent pyrin from assembling with ASC and pro-
caspase-1 to form a functional inflammasome. Although col-
chicine is also effective in the treatment of gouty arthritis,
which is mediated by the NLRP3 inflammasome, colchicine
does not inhibit the activity of theNLRP3 inflammasome, but it
appears to interfere with the uptake of urate crystals by macro-
phages (30).
One of the reasons for the controversy regarding pyrin func-
tion is the lack of mouse genetic evidence to support a role for
mouse pyrin in caspase-1 activation. Mouse pyrin lacks the
C-terminal B30.2/SPRY domain, which harbors most of the
FMF mutations, and therefore may not have a similar function
and/or regulation as the human protein. Supporting this, mice
with a targeted disruption of the pyrin gene do not show any
obvious defects in inflammation (26), whereas mice with
knock-in of humanized pyrin transgenes carrying FMF-associ-
ated mutations in the B30.2/SPRY domain show constitutive
caspase-1 activation in macrophages and severe inflammation
similar to FMF (11). Interestingly, knock-in of a humanized
pyrin transgene without FMF-associated mutations leads to
embryonic lethality in mice (11). These observations suggest
that the B30.2/SPRY domain regulates the inflammasome
activity of human pyrin. The absence of this domain in mouse
pyrin might lead to an altered or even loss of pyrin inflam-
masome activity. Consistent with this, our results shows that
the expression of mouse pyrin could be up-regulated by LPS or
IFN treatment in peritoneal macrophages (Fig. 5A). However,
treatment of these macrophages with anisomycin did not
induce caspase-1 activation or result in IL-1 release, whereas
treatment with the NLRP3 inflammasome activator ATP did
both (Fig. 5B). Unlike human pyrin, mouse pyrin did not inter-
actwith PSTPIP1,4 which could explain the recent observations
that knock-in of the disease-associated PSTPIP1 A230T
mutant inmice does not lead to development of an autoinflam-
4 L. Solorzano, P. Datta, T. Fernandes-Alnemri, and E. S. Alnemri, unpublished
data.
FIGURE 5. Anisomycin does not activate caspase-1 in mouse peritoneal
macrophages.A, immunoblots of pyrin andASC inmouse peritonealmacro-
phages treated with LPS (upper and middle panels) or IFN (lower panel) for
the indicated times. B, immunoblots of caspase-1 or IL-1 in culture superna-
tants (Sup) of mouse peritoneal macrophages treated with LPS plus ATP or
LPSplus anisomycin (aniso) as indicated. Immunoblots of caspase-1 andpyrin
in the cell lysates (Lys) are indicated. procasp-1, procaspase-1.
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matory disease (31). Together, these observations further sup-
port the idea that mouse pyrin is not activated by the same
signaling pathway(s) that activate human pyrin.
In conclusion, we have identified the ribotoxic stress path-
way as an important mediator of pyrin inflammasome activa-
tion.We propose that the activation of p38MAPK signaling by
ribotoxic stress stimulates the recruitment of ASC to the
pyrin homotrimer, which induces its oligomerization. It
remains to be determined whether p38MAPK directly phos-
phorylates the pyrin homotrimer to induce the assembly of
the pyrin inflammasome.
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